雑誌文献を検索します。書籍を検索する際には「書籍検索」を選択してください。

検索

書誌情報 詳細検索 by 医中誌

Japanese

Use of Tocilizumab, an Antibody against Interleukin-6 Receptor, for the Treatment of Neuromyelitis Optica Takashi Yamamura 1 , Manabu Araki 2 1Department of Immunology, National Institute of Neuroscience, National Center of Neurology and Psychiatry 2Multiple Sclerosis Center, NCNP Hospital, National Center of Neurology and Psychiatry Keyword: 視神経脊髄炎 , IL-6 , IL-6受容体 , トシリズマブ , 神経原性疼痛 , neuromyelitis optica , IL-6 , IL-6 receptor , tocilizumab , neurogenic pain pp.1159-1165
Published Date 2014/10/1
DOI https://doi.org/10.11477/mf.1416200004
  • Abstract
  • Look Inside
  • Reference

Abstract

Our lab has previously shown that Interleukin (IL)-6- dependent production of autoantibodies against aquaporin 4 in plasmablasts may play a central role in the pathogenesis of neuromyelitis optica (NMO). In this study, we explored the efficacy of tocilizumab, a humanized antibody against IL-6 receptor, in intractable cases of NMO. Eight NMO patients who were unresponsive to current treatments received monthly injections of tocilizumab for at least one year. Tocilizumab significantly reduced the annual relapse rate, neurogenic pain, and fatigue in NMO patients. These results indicate that IL-6 signaling plays a crucial role in the pathogenesis of NMO and highlight the value of IL-6 receptor inhibition for the treatment of NMO.


Copyright © 2014, Igaku-Shoin Ltd. All rights reserved.

基本情報

電子版ISSN 1344-8129 印刷版ISSN 1881-6096 医学書院

関連文献

もっと見る

文献を共有